BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37356359)

  • 1. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
    Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
    ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
    Mosele F; Remon J; Mateo J; Westphalen CB; Barlesi F; Lolkema MP; Normanno N; Scarpa A; Robson M; Meric-Bernstam F; Wagle N; Stenzinger A; Bonastre J; Bayle A; Michiels S; Bièche I; Rouleau E; Jezdic S; Douillard JY; Reis-Filho JS; Dienstmann R; André F
    Ann Oncol; 2020 Nov; 31(11):1491-1505. PubMed ID: 32853681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.
    Stenzinger A; Cuffel B; Paracha N; Vail E; Garcia-Foncillas J; Goodman C; Lassen U; Vassal G; Sullivan SD
    Oncologist; 2023 May; 28(5):e242-e253. PubMed ID: 36961477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations to improve the clinical adoption of NGS-based cancer diagnostics in Singapore.
    Tan DS; Tan DS; Tan IBH; Yan B; Choo SP; Chng WJ; Hwang WYK
    Asia Pac J Clin Oncol; 2020 Aug; 16(4):222-231. PubMed ID: 32301274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
    Schwartzberg L; Daniel D; Vaena D; Slater D; Staszewski H; Fang B; Seneviratne L; Yu E; Price R; Szado T; Meyer CS; Shah A; Ma E
    Future Oncol; 2023 Jun; 19(20):1397-1414. PubMed ID: 37318757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group.
    Mosele MF; Westphalen CB; Stenzinger A; Barlesi F; Bayle A; Bièche I; Bonastre J; Castro E; Dienstmann R; Krämer A; Czarnecka A; Meric-Bernstam F; Michiels S; Miller R; Normanno N; Reis-Filho J; Remon J; Robson M; Rouleau E; Scarpa A; Serrano C; Mateo J; André F
    Ann Oncol; 2024 May; ():. PubMed ID: 38834388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next Generation Sequencing-Based Germline Panel Testing for Breast and Ovarian Cancers in Pakistan.
    Tariq H; Gul A; Khadim T; Ud-Din H; Tipu HN; Asif M; Ahmed R
    Asian Pac J Cancer Prev; 2021 Mar; 22(3):719-724. PubMed ID: 33773534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
    Vanderpoel J; Stevens AL; Emond B; Lafeuille MH; Hilts A; Lefebvre P; Morrison L
    J Med Econ; 2022; 25(1):457-468. PubMed ID: 35289703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
    Bonanno L; Pavan A; Ferro A; Calvetti L; Frega S; Pasello G; Aprile G; Guarneri V; Conte P;
    Oncologist; 2020 Dec; 25(12):e1996-e2005. PubMed ID: 32557976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
    Bestvina CM; Waters D; Morrison L; Emond B; Lafeuille MH; Hilts A; Lefebvre P; He A; Vanderpoel J
    J Med Econ; 2024; 27(1):292-303. PubMed ID: 38391239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Cancer, Rare Tumors, and Cancers of Unknown Primary Origin in Clinical Practice.
    R Teixeira M; Oliveira J; Borralho P; O Fernandes MG; Almodovar T; Fernandes I; Macedo D; Ferreira A; Barroso A; Teixeira E; Machado JC
    Acta Med Port; 2022 Sep; 35(9):677-690. PubMed ID: 35816050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.
    Kluska A; Balabas A; Paziewska A; Kulecka M; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2015 May; 8():19. PubMed ID: 25948282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
    Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
    Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Ion Torrent PGM sequencing workflow for the routine rapid detection of BRCA1 and BRCA2 germline mutations.
    Zanella I; Merola F; Biasiotto G; Archetti S; Spinelli E; Di Lorenzo D
    Exp Mol Pathol; 2017 Apr; 102(2):314-320. PubMed ID: 28263838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
    Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.